You have 9 free searches left this month | to do more

magrolimab

Magrolimab is a drug used to treat Acute Myeloid Leukemia, Solid Tumor, B-Cell Lymphoma, and other conditions. Magrolimab is being actively studied in 13 studies and prior, has been studied in 2.

Top SponsorsTop SitesTop Investigators
Gilead SciencesPrincess Alexandra HospitalSabine Mueller, MD, PhD
M.D. Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
National Cancer Institute (NCI)Astera Cancer Care
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
G
Study Evaluating the Safety and Effectiveness Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia (AML)
Not yet recruiting
  • Acute Myeloid Leukemia
  • Magrolimab
  • +3 more
  • Houston, Texas
    MD Anderson Cancer Center
2022-02-03
Feb 3, 2022
U
Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors
Not yet recruiting
  • Brain Cancer
  • +5 more
  • Magrolimab
  • San Francisco, California
  • +1 more
2022-03-21
Mar 21, 2022
G
Study of Magrolimab Combinations in Participants With Relapsed/Refractory Multiple Myeloma
Active, not recruiting
  • Multiple Myeloma
  • Magrolimab
  • +5 more
  • Tucson, Arizona
  • +6 more
2022-03-30
Mar 30, 2022
N
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
Suspended
  • Follicular Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
S
Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
Not yet recruiting
  • Hodgkin Lymphoma
  • +3 more
  • Magrolimab
  • +2 more
  • Stanford, California
    Stanford University
2021-08-16
Aug 16, 2021
G
Study of Magrolimab in Participants With Solid Tumors
Recruiting
  • Solid Tumor
  • Santa Rosa, California
  • +10 more
2022-03-21
Mar 21, 2022
M
Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia
Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-11-16
Nov 16, 2021
G
Study of Magrolimab Combinations in Participants With Myeloid Malignancies
Recruiting
  • Myeloid Malignancies
  • Magrolimab
  • +6 more
  • Birmingham, Alabama
  • +12 more
2022-04-06
Apr 6, 2022
G
Study to Evaluate the Safety and Efficacy of Magrolimab Combination Therapy in Adults With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer
Recruiting
  • Triple-Negative Breast Cancer
  • Magrolimab
  • +3 more
  • Santa Rosa, California
  • +11 more
2022-03-30
Mar 30, 2022
G
Study of Magrolimab Combination Therapy in Participants With Head and Neck Squamous Cell Carcinoma
Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Magrolimab
  • +6 more
  • Palo Alto, California
  • +13 more
2022-03-24
Mar 24, 2022
G
Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies
Active, not recruiting
  • Hematological Malignancies
  • Duarte, California
  • +26 more
2022-02-03
Feb 3, 2022
G
Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer - 2020
Completed
Has Results
  • Solid Tumor
  • Colorectal Cancer
  • Los Angeles, California
  • +7 more
2021-02-08
Feb 8, 2021
G
Trial of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy - 2020
Completed
  • Ovarian Cancer
  • Chicago, Illinois
  • +5 more
2021-07-26
Jul 26, 2021
G
Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia
Active, not recruiting
  • Acute Myeloid Leukemia
  • Magrolimab
  • +6 more
  • Duarte, California
  • +25 more
2022-02-04
Feb 4, 2022
G
Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Active, not recruiting
  • Non Hodgkin Lymphoma
  • Magrolimab
  • +3 more
  • Birmingham, Alabama
  • +19 more
2022-01-04
Jan 4, 2022
G
Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)
Active, not recruiting
  • Myelodysplastic Syndromes
  • Magrolimab
  • +2 more
  • Birmingham, Alabama
  • +153 more
2022-02-03
Feb 3, 2022